Allhorn Maria, Collin Mattias
Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
Ann N Y Acad Sci. 2009 Sep;1173:664-9. doi: 10.1111/j.1749-6632.2009.04739.x.
The enzyme EndoS from Streptococcus pyogenes is an immunomodulatory molecule hydrolyzing the conserved glycans in the effector part of immunoglobulin G (IgG). EndoS is remarkably specific for IgG, and hydrolysis has profound effects on IgG effector functions. EndoS pretreatment of IgG, or direct administration to animals with experimental antibody-mediated autoimmune diseases, inhibits development of disease or cures animals from established disease. The properties of EndoS make it a unique experimental tool and an attractive alternative to current therapies of conditions involving pathogenic antibodies. This review describes the discovery of EndoS, the effects of EndoS on IgG effector functions in vitro and in vivo, the biotechnological potential of EndoS, and the outcomes of EndoS treatment in animal models of autoimmunity.
化脓性链球菌的EndoS酶是一种免疫调节分子,可水解免疫球蛋白G(IgG)效应部分的保守聚糖。EndoS对IgG具有显著的特异性,水解对IgG效应功能有深远影响。对IgG进行EndoS预处理,或直接给予患有实验性抗体介导的自身免疫性疾病的动物,可抑制疾病发展或治愈已患疾病的动物。EndoS的特性使其成为一种独特的实验工具,也是目前涉及致病性抗体病症治疗方法的有吸引力的替代方案。本文综述了EndoS的发现、EndoS在体外和体内对IgG效应功能的影响、EndoS的生物技术潜力以及EndoS在自身免疫动物模型中的治疗结果。